Verastem, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Verastem, Inc. (VSTM) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $4.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2025-11-04.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2025-11-04
- Verastem, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-06-30 was $4.00K.
- Verastem, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was -$17.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2024-06-30 | $4.00K 10-Q · filed 2025-11-04 | -$13.00K derived: sum of 2 quarters · filed 2025-11-04 |
| 2024-03-31 | -$17.00K 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |